 Haaretz | Teva halts tests of cancer drug biosimilar Haaretz Developing a biosimilar generic version of Rituxan (rituximab) is a key goal of the joint venture that Teva, the biggest generic drugmaker in the world, formed in January 2009 with the Swiss company Lonza. Suspending third-phase clinical testing of the ... |
